Therapeutical effects of PPAR agonists assessed by biomarker modulation.
The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension. Activators of the nuclear receptors peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors pre-disposing to atherosclerosis. Fibrates are hypolipidemic drugs operating through activation of PPARalpha, whereas glitazones are insulin sensitizers activating PPARgamma. In addition, these drugs exert pleiotropic and anti-inflammatory actions. This review will focus on the different effects of fibrates and glitazones, as measured by biomarker modulation, on the development of atherosclerosis and cardiovascular disease.
Chinetti-Gbaguidi
G
G
UR 545 INSERM, Institut Pasteur de Lille, Université de Lille 2, Lille, France. giulia.chinetti@pasteur-lille.fr
Fruchart
J-C
JC
Staels
B
B
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D002995:Clofibric Acid / Q000494:pharmacology; D006801:Humans; D007249:Inflammation; D024821:Metabolic Syndrome / Q000473:pathology; D047493:PPAR alpha / Q000819:agonists*; D047495:PPAR gamma / Q000819:agonists*; D045162:Thiazolidinediones / Q000494:pharmacology
D015415:Biomarkers; D047493:PPAR alpha; D047495:PPAR gamma; D045162:Thiazolidinediones; D002995:Clofibric Acid